SEC recommends Phase 1 trials of Reliance's Covid vaccine candidate

The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance Life Sciences' two-dose Covid-19 vaccine candidate. Now, approval by the Drugs Controller General of India (DCGI) is required, following which Reliance Life Sciences can commence Phase 1 trials of the Covid-19 vaccine.